Drug Type Small molecule drug |
Synonyms BEBT 209, KCBT-0191 |
Target |
Action inhibitors |
Mechanism CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | Phase 3 | China | 23 May 2022 | |
Advanced Triple-Negative Breast Carcinoma | Phase 2 | China | 03 Apr 2023 | |
Advanced breast cancer | Phase 1 | China | 15 Jul 2019 |
Phase 2 | 36 | BEBT-209 + Gemcitabine and Carboplatin | mjoaeygcoj(faervoffoh) = lqdvmtliny ijgurpkdbq (zbzylhqurs, 13.9 - 68.4) View more | Positive | 30 May 2025 | ||
NCT06685796 (NEWS) Manual | Phase 2 | - | BEBT-209联合化疗 (辅助治疗后早期复发(12个月内复发)) | hggbpkpoor(qqhihbtkzo) = aouwlokzon nsyueiskuk (baawqdwbgf ) View more | Positive | 19 Dec 2024 | |
BEBT-209联合化疗 (接受过至少一线全身治疗的转移性TNBC患者) | hggbpkpoor(qqhihbtkzo) = dqhgflygbj nsyueiskuk (baawqdwbgf ) View more |